First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial
一线治疗EGFR突变型非小细胞肺癌患者，比较奥莫替尼（EGFR酪氨酸激酶抑制剂）联合阿帕替尼（VEGFR抑制剂）与奥莫替尼单药治疗的疗效：一项随机、多中心、II期临床试验
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02550-y
Zhang, Fan; Zheng, Zhendong; Zhang, Hongmei; Yan, Xiaolong; Liu, Zhefeng; Yang, Fan; Wen, Juyi; Gan, Xin; Wu, Lin; Cang, Shundong; Wang, Hongmei; Zhao, Jun; Peng, Liang; Li, Xiaosong; Fan, Zaiwen; Shen, Ge; Zhou, Qiong; Zou, Jinjing; Xu, Yu; Zhang, Lei; Zhao, Mingfang; Cai, Shangli; Hu, Yi
肺癌
肿瘤
肿瘤免疫
信号转导
EGF
EGFR
细胞生物学
VEGF
